Segmed, Verily band together to expand access to real-world imaging data. Pairing aims to to support patient-centered, data-driven healthcare innovation. April 30, 2026 Managing Editor Segmed Inc. is partnering with Verily to increase access to de-identified imaging datasets. Through the collaboration, Segmed is making its de-identified, diagnostic-grade imaging and associated clinical data more available by enabling researchers to explore curated datasets within Verily's precision health platform, Pre Exchange and Workbench environment, secure platforms designed to accelerate precision health research and discovery. The partnership reflects Segmed's commitment to supporting rigorous, privacy-first research while lowering barriers to entry for investigators across academia, life sciences, and healthcare artificial intelligence (AI), Segmed executives claim. "Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," Segmed CEO David Gascoigne said. "By partnering with Verily, we're expanding responsible access to high-quality, de-identified imaging datasets, helping researchers generate insights faster to accelerate the development of diagnostics and therapies." Segmed's initial dataset available through Pre Exchange focuses on breast cancer and includes a longitudinal cohort of patients who underwent at least one digital breast tomosynthesis (DBT) exam and biopsy-proven malignant lesions. This dataset is drawn from Segmed's broader global imaging platform, which includes approximately 150 million de-identified imaging exams spanning modalities such as CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA. "This partnership with Segmed is an important step forward in advancing AI-powered precision health," Verily Chief Revenue Officer Bharat Rajagopal stated. "By integrating Segmed's curated real-world imaging and associated clinical data into Pre, we are empowering researchers with the comprehensive, multimodal data resources they need to unlock new insights and accelerate discovery." This partnership reflects Segmed's ongoing efforts to support patient-centered, data-driven healthcare innovation by enabling secure, scalable access to real-world imaging data and associated clinical data within trusted research environments. Segmed Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 150 million de-identified, standardized imaging datasets through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level.

Verily Health has announced that Verily Workbench, its scalable trusted research environment for biomedical data analysis and AI development, is now generally available on Amazon Web Services. The platform enables researchers to analyse healthcare data with built-in compliance and integrated AI tools. Workbench offers zero cloud cost markup, allowing organisations to use existing AWS accounts and negotiated rates. The platform includes native integration with NVIDIA AI tools and supports multicloud operations across AWS and Google Cloud Platform. Researchers can access free standard tier accounts through Verily's Exchange solution. The platform currently serves life sciences, health system and government customers, including the NIH's All of Us Research Programme, which supports over 20,000 researchers worldwide. Verily holds SOC 2 Type 2 and ISO/IEC 27001 certifications.

Dallas-Based Verily raises $300M, ending Alphabet's controlling stake. Verily graduated from Google X 10 years ago as one of Alphabet's earliest "Other Bets," focusing on breakthrough science and health tech innovation. Its new round was led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors. The lobby of Verily's headquarters at Cypress Waters in Dallas. [Photo: Verily] Dallas-based Verily has raised a new $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, for the next phase of its precision health AI strategy. With this funding round, Alphabet will now be a significant minority investor in Verily, while no longer having a controlling stake. "Today is an important step in our mission to bring the promise of precision health to everyone," said Stephen Gillett, chairman and CEO of Verily,. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal." "Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare," Gillett added in a statement. With the investment, Verily has transitioned its legal structure from an LLC to a corporation, and will now operate as Verily Health Inc. The company said it aims to boost its AI-native precision health platform strategy and roadmap to help customers streamline their healthcare data, while modeling and deploying actionable intelligence into research and care workflows. Verily is headquartered in the Cypress Waters development in Dallas, just southeast of Coppell. The company relocated its HQ from South San Francisco in 2024, bridging its East and West Coast operations in North Texas while maintaining its presence in the Bay Area. Using AI to transform healthcare. Recently, Verily has established several commercial partnerships, including a new collaboration with Samsung's Galaxy Watch to help life sciences customers advance clinical research through biomarker development on the Pre platform. The company has also announced a strategic partnership with Salesforce for the integration of the Verily Pre Platform with Agentforce Health to fuel enterprise precision health solutions. Verily said the new partnerships are strengthened by its recent collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, who are using the Verily Pre platform for AI-driven research and care transformation. Gideon Yu, founder and managing partner of Series X Capital, said his firm "was established in collaboration with Google's X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies." He added that his firm is "extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health." 'A generational opportunity' Graduating from Google X 10 years ago as one of Alphabet's earliest "Other Bets," Verily focuses on breakthrough science and health tech innovation. "At Alphabet, we applaud Verily's tenacity in using technology to address longstanding challenges in the healthcare industry," said Ruth Porat, president and. chief investment officer at Alphabet and Google. "Bringing in new investors, alongside Alphabet's ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform." Richard Zane, MD, UCHealth chief medical and innovation Officer, said that collaborating with Verily to craft a data framework "creates a generational opportunity" to improve medicine. "This collaboration helps unlock the long-promised potential of personalized care," Zane added, "benefiting our patients and, ultimately, all patients. It will save lives, and we're eager to get started." Other recent moves by Verily. Last October, Verily launched a new consumer health app, Verily Me, designed to close gaps in care and enable people to stay informed and engaged in their health journey over time. Last April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson's Research. The grant's goal is to generate a comprehensive molecular dataset to advance Parkinson's disease research. Track Dallas-Fort Worth's business and innovation landscape with its curated news in your inbox Tuesday-Thursday. One quick signup, and you're done. R E A D N E X T. * The Last Word: Arete Health CEO On a First-of-Its-Kind Health and Wellness Program for Dallas Creatives Creatives Care Dallas brings virtual care, behavioral health, 2,000+ medications with zero copay, and more to Dallas County's gig workers. The community initiative is powered by Arete Health Shield in partnership with the Dallas Music Office. * Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth North Texas has plenty to see, hear, and watch. Here are its editors' picks. Plus, you'll find more selections to "save the date." * Alphabet-Owned Verily Launches AI-Powered App to Manage Healthcare and Personalize Insights Unveiled at HLTH USA 2025, the Dallas-based precision health company's Verily Me app blends clinical guidance and AI-driven tools to help people stay informed, connected, and proactive in managing their health. * North Texas Innovation Is Boundary-Breaking. Nominations for the Awards That Prove It Close Sept. 12 D CEO and Dallas Innovates have expanded The Innovation Awards 2026 with more individual and company categories this year. Now is your chance to be part of the region's defining recognition for innovators. * SVP Dallas Names Catherine Cuellar as Its Next CEO A familiar figure in Dallas arts, civic innovation, and public service, Cuellar will succeed longtime CEO Tony Fleo following a months-long search as Social Venture Partners Dallas plans its next 25 years. Share via: